extract: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -53,6 +53,12 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir
 
 At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated.
 
+
+### Additional Evidence (challenge)
+*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
+
+Sarcopenic obesity risk from GLP-1-induced muscle loss (15-40% of weight lost is lean mass) combined with high discontinuation rates may create NEW healthcare costs that offset cardiovascular and metabolic savings. Elderly patients with sarcopenic obesity face increased fall risk, fractures, and disability—potentially requiring MORE healthcare utilization, not less. This directly challenges the net cost-savings assumption, especially in the Medicare population.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
 
 No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
+
+The 64.8% one-year discontinuation rate creates a specific harm mechanism: patients who discontinue regain weight preferentially as fat while muscle lost during treatment is not regained, resulting in sarcopenic obesity with worse body composition than baseline. This weight cycling pattern transforms discontinuation from merely an adherence problem into an iatrogenic risk.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json

@@ -0,0 +1,24 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-risk.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 1,
+    "rejected": 1,
+    "fixes_applied": [
+      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-risk.md:set_created:2026-03-16"
+    ],
+    "rejections": [
+      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-risk.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md

@@ -7,9 +7,13 @@ date: 2025-07-01
 domain: health
 secondary_domains: []
 format: review
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, sarcopenia, muscle-loss, elderly, safety, lean-mass]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -50,3 +54,11 @@ WHY ARCHIVED: Counter-evidence to the GLP-1 benefit thesis — sarcopenia risk m
 EXTRACTION HINT: The intersection of muscle loss + high discontinuation rates is the key risk — evaluate as a challenge to the cost-savings thesis, not just a clinical side effect
 
 flagged_for_astra: ["GLP-1-induced muscle loss in elderly has parallels to spaceflight muscle atrophy — different mechanism but similar functional consequences"]
+
+
+## Key Facts
+- Natural aging reduces skeletal muscle mass by 12-16%
+- Sarcopenic obesity prevalence in older adults: 10-20%
+- 15-40% of total weight lost on GLP-1s is lean body mass, with some analyses suggesting up to 60%
+- 64.8% of GLP-1 patients discontinue within one year
+- Next-generation GLP-1 compounds are being developed with claims to improve muscle preservation